Seizures are a well known side effect of BU administration, especially at the high doses used for pre-transplant conditioning regimens; they occur in 10% of adults and 7.5% of children, and are effectively prevented by an antiepileptic prophylaxis both in paediatric and adult population. 1 The most commonly used drugs in this setting are diphenylhydantoin and carbamazepine, but these molecules are not active until a sufficient blood level is reached, which may take several days and frequent dose-titration. Furthermore, both these drugs may have relevant interactions with the metabolism of other medications commonly used during hematopoietic SCT (HSCT), including antibiotics or even BU itself. 2 Benzodiazepines have no major interaction with other drugs, and are commonly used as oral prophylaxis in children. Some reports suggest that lorazepam, given either orally or intravenously, may represent an alternative prophylaxis during BU treatment. 3 Continuous i.v. infusion of lorazepam is a well known therapy and prophylaxis for epileptic status, allowing a rapid achievement of protective blood levels, with longer efficacy and decreased respiratory depression compared to diazepam. 4 The rapid effect on the central nervous system of a drug is often associated with lipid solubility, which allows an initial peak followed by redistribution with variable blood levels, until saturation, therefore with little prediction of clinical efficacy. Continuous i.v. infusion prevents plasma peak levels, with rapid achievement of saturation, thus providing a more reliable therapeutic effect. 5 The only caveat is a possible withdrawal syndrome at lorazepam discontinuation, as reported in children after a 3-week infusion during intensive care treatment. 6 On the basis of this assumption, we used continuous i.v. infusion of lorazepam together with BU-based conditioning regimen in 16 consecutive children, aged 1-17 years, who underwent HSCT for neuroblastoma (n ¼ 9), AML (n ¼ 5), SCID (n ¼ 1) and Ewing sarcoma (n ¼ 1). Thirteen patients received oral BU at the standard dose (16 mg/kg in 16 doses over 4 days), while three patients, aged 12, 37 and 38 months, received i.v. BU at the dose of 1.2 mg/kg/dose q6 h for a total of 16 doses, adjusted to start from the 7th dose according to the pharmacokinetic results.
BU levels were analysed in plasma by a validated HPLC assay, involving protein precipitation, precolumn derivatization, liquid/liquid extraction and ultraviolet detection according to Henner et al. 7 BU concentration at the steady-state was used to monitor the disposition of the drug, to ensure efficacy and prevent toxicity. 8 The following conditioning regimens were used: BU þ melphalan for neuroblastoma and Ewing sarcoma; BU þ melphalan þ CY for AML and BU þ CY in the patient with SCID. No unexpected toxicities were observed; nausea and emesis were moderate.
All patients received continuous i.v. infusion of lorazepam, at the dose of 0.1 mg/kg/day, with a maximum dose of 2 mg/day; thus, in some patients the individual dose was between 0.04 and 0.1 mg/kg/day. Infusion was started 12 h before the first BU dose, and then discontinued 24 h after the last dose; thus, the total duration of the drug infusion was 5.5 days.
Central venous line was used as access in all cases. This regimen was very well tolerated by all patients; the only observed side effect was an inconstant drowsiness. None of the treated patients developed seizures, during or after BU treatment, or had withdrawal-related symptoms. Also in children treated with i.v. BU, administered in a single daily dose, 9 prophylaxis is needed for the whole day, and we had no problems. No incompatibility with other drugs was reported and, from the nursing standpoint, continuous i.v. infusion was considered easy and practical.
In our experience continuous infusion of lorazepam is a useful therapeutic option for prophylaxis of seizures during potentially epileptogenic conditioning regimens. This schedule proved to be feasible (also according to the possible difficulties when using oral prophylaxis), safe and effective.
Continuous i.v. infusion of lorazepam is easier to administer and may offer rapid protection against seizures, therefore representing a useful prophylactic alternative. 
